The rationale for using apoA-I as a clinical marker of cardiovascular risk.
about
Proteomic analysis of fructose-induced fatty liver in hamstersMass spectrometric determination of apolipoprotein molecular stoichiometry in reconstituted high density lipoprotein particles.Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction.EPR assessment of protein sites for incorporation of Gd(III) MRI contrast labelsThe Association between Apolipoprotein A-II and Metabolic Syndrome in Korean Adults: A Comparison Study of Apolipoprotein A-I and Apolipoprotein BIntroduction: Apolipoproteins and guidelines for prevention of cardiovascular disease.The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease.Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase DeficiencySerum Apo A-1 and Its Role as a Biomarker of Coronary Artery Disease.The novel diagnostic biomarkers for focal segmental glomerulosclerosis.Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20-38 years in China.Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities StudyCD36 is significantly correlated with adipophilin in human carotid lesions and inversely correlated with plasma ApoAI.Potential serum biomarkers associated with mild and severe leptospirosis infection: A cohort study in the Malaysian population.Functionalized self-assembling peptide hydrogel enhance maintenance of hepatocyte activity in vitro.COUP-TFII switches responses of venous endothelium to atherosclerotic factors through controlling the profile of various inherent genes expression.Apolipoprotein B/A1 ratio is associated with free androgen index and visceral adiposity and may be an indicator of metabolic syndrome in male children and adolescents.Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.
P2860
Q33353210-637989BF-940E-4053-822B-380D7A34A891Q33403980-2B9D6E0B-AAEA-4AC3-B56B-190F7161156CQ34457410-3D3EC67F-E587-456B-8AD1-A1749ADF3826Q34680348-CB83A6BF-55EE-4197-9417-BA5AB3C5D84FQ35770053-92435D76-A9C3-4918-BD4A-42A8DBAF6EF0Q36455879-DDFCB36D-FFC5-4BE4-A795-8F1BA179DA97Q36455901-EB802ED9-646A-45D4-8F1C-5D9AA78E7A4BQ36536256-C2D35787-87F8-4869-8799-BD8C8792D2C9Q37180476-582A58B4-EFDA-4460-B4A4-FF5BEE7B85C4Q37603797-E47C8857-7C38-4048-AA59-643B7D2F9787Q37699843-909BE4CB-CC8F-4260-BF2B-061365470C20Q37734592-F428806A-1C55-43F4-9FF0-FFA1410257D8Q38372740-001CC9EC-4E29-4030-87F4-4A0C65943AECQ39933876-7A717016-E970-4F43-8E3C-08A06ADAF96AQ40194995-29C8806C-170C-421B-BA10-B2DC38A7B45BQ41978560-D9A8C096-CE56-4C9D-A88D-5D61701A509AQ42479752-ACB9A287-6FBF-4A8F-9DCC-8EE915470B52Q51385015-9E8BF552-08D9-4E8C-8678-1CA72C886245Q51809299-1D1BE015-E528-4BC4-AEB1-18280282848F
P2860
The rationale for using apoA-I as a clinical marker of cardiovascular risk.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The rationale for using apoA-I as a clinical marker of cardiovascular risk.
@ast
The rationale for using apoA-I as a clinical marker of cardiovascular risk.
@en
type
label
The rationale for using apoA-I as a clinical marker of cardiovascular risk.
@ast
The rationale for using apoA-I as a clinical marker of cardiovascular risk.
@en
prefLabel
The rationale for using apoA-I as a clinical marker of cardiovascular risk.
@ast
The rationale for using apoA-I as a clinical marker of cardiovascular risk.
@en
P2860
P1476
The rationale for using apoA-I as a clinical marker of cardiovascular risk.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2796.2006.01647.X
P407
P577
2006-05-01T00:00:00Z